BackBlackRock Health Sciences Trust Overview
BlackRock Health Sciences Trust

BlackRock Health Sciences Trust Price to Sales

Valuation check: BME's P/S ratio is 6.28, below the sector sector average of 10.72.

Get informed when a big investor buys or sells

+ Follow

Price to Sales

6.28

Price to Sales

6.28

Price-to-Sales ratio compares a company's stock price to its revenue per share. A lower P/S ratio may indicate that the stock is undervalued relative to its sales.

Price to Sales (Comparison Companies)

Loading

Price to Sales History

Loading

Price to Sales Comparison

Loading

BlackRock Health Sciences Trust (BME) FAQ

BlackRock Health Sciences Trust's price-to-sales ratio stands at 6.28. That is below the sector sector average of 10.72. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

BlackRock Health Sciences Trust sits lower the its sector benchmark (10.72) with a P/S ratio of 6.28. That is roughly 41.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 6.28 is attractive depends on BlackRock Health Sciences Trust's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how BlackRock Health Sciences Trust's P/S ratio evolved across reporting periods, while the comparison chart places BME next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.